Kedrion warned it may struggle to deliver vital plasma-based medicines to patients in Iran if shipping disruption through the Strait of Hormuz persists. The risk is primarily logistical and geopolitical, with potential supply-chain delays rather than an immediate financial or market-wide shock.
Kedrion warned it may struggle to deliver vital plasma-based medicines to patients in Iran if shipping disruption through the Strait of Hormuz persists. The risk is primarily logistical and geopolitical, with potential supply-chain delays rather than an immediate financial or market-wide shock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately negative
Sentiment Score
-0.35
